Why Disc Medicine, Inc.’s (IRON) Stock Is Down 5.11%
As of Friday, July 31, Disc Medicine, Inc.’s IRON share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Disc Medicine, Inc.’s (IRON) Stock Is Up 5.61%
As of Tuesday, July 07, Disc Medicine, Inc.’s IRON share price has surged by 5.61%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Disc Medicine, Inc.’s (IRON) Stock Is Down 5.34%
As of Tuesday, June 02, Disc Medicine, Inc.’s IRON share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Michael Rose
Why Disc Medicine, Inc.’s (IRON) Stock Is Down 6.00%
As of Thursday, March 12, Disc Medicine, Inc.’s IRON share price has dipped by 6.00%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Disc Medicine, Inc.’s (IRON) Stock Is Up 7.48%
As of Monday, March 09, Disc Medicine, Inc.’s IRON share price has surged by 7.48%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | IRON | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,073.3 | $288.9 | 60% |
|
| Shares Out (Mil) | 38.7 | 54.0 | 42% |
|
| Institutional Ownership | 99.6% | 93.1% | 91% |
|
| Float (Mil) | 32.9 | 41.4 | 38% |
|
| Beta | 2.07 | 0.94 | 93% |
|
| Avg Daily Volume (000s) | 483 | 480 | 59% |
|
| Price Change (52-week) |
30.4% | 59.9% | 71% |
|
| Growth | IRON | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (59.0%) | (10.1%) | 5% |
|
| EPS (5yr) | (14.8%) | 15.9% | 19 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (27.2%) | (15.6%) | 23% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($1.740) | ($6.671) | ($7.260) | |
| Month Ago EPS | ($1.736) | ($6.682) | ($7.230) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.853) | ($7.161) | ($7.505) | |
| Year/Year Chg | 13.1% | 11.0% | (4.7%) | |
| Financials | IRON | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($246) | ($43) | 6% |
|
| EPS (TTM) | ($6.557) | ($1.500) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($198) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($29) | $2 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $61 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $2,299 | $190 | 51% |
|
| Valuation | IRON | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.76 | 2.84 | 77% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IRON | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (35.1%) | (47.7%) | 15% |
|
| ROE | (39.1%) | (55.0%) | 18% |
|
| Liabilities to Assets | 12.4% | 29.6% | 8% |
|
| F-Score | 1 | 3 | 1% |
|
Disc Medicine, Inc. did not pass any screens on 9/2/2026.
